###### Strengths and limitations of this study

-   Annual mortality time-series data from 161 locations across all 31 provinces of China.

-   Multilevel random intercept-slope models to investigate spatiotemporal variation.

-   Recognised classification of health service 'amenable' mortality.

-   Use of 'negative outcome' technique with health service 'non-amenable' mortality.

-   Data on geographic variation in health policy implementation is needed.

Introduction {#s1}
============

Commentators suggest that a universal health insurance which provides access to good quality health services not only helps enhance health and prevents disease,[@R1] but also serves to reduce socioeconomic inequity[@R2] and strengthens the workforce.[@R3] The pursuit for universal health coverage has been reflected in developments over the past 10--15 years in China, including the landmark reforms of 2009. China\'s government began to re-establish rural health insurance from 2002 in which all rural Chinese residents were eligible to enrol.[@R4] Attention then focused on cities with the launch of the urban resident basic health insurance in 2007.[@R5] This was followed by China\'s landmark reforms in 2009, which led to the rapid expansion of health insurance to over 90% of the population by the end of 2010.[@R6] Five years on, we investigated whether the Chinese government\'s investment of CN¥850 billion (US\$125 billion) had early impacts on public health.

While universal health coverage is regarded as central to social and economic policy[@R3] and a vital component for achieving health equity,[@R7] the scientific evidence of health *its* impact is mixed.[@R8] Population-wide investigations of the impact of universal health insurance are rare,[@R9] with most focusing either on young children[@R10] or the elderly.[@R14] [@R15] Previous work on the implementation of universal health coverage from 1995 onwards in Taiwan, for example, has reported a rise in health service utilisation among the newly insured[@R16] and a marginally steeper rise in life expectancy within communities that had higher mortality rates before 1995.[@R17] Yet both favourable and null findings have been reported on possible improvements in health status and reductions in mortality.[@R18] [@R19] The potential health impact of implementing universal health coverage is uncertain in a society as socially and geographically diverse as China.[@R20] Furthermore, given the proliferation of particular diseases and causes of death amenable to healthcare intervention in particular areas of China, it is unlikely that any early impacts on health have been uniform across this vast country.

Accordingly, the aim of our study was to use a nationally representative time series data (2006--2012) across mainland China spanning the period prior and subsequent to the 2009 reform to explore for early impacts of the expansion of universal coverage on public health.

Methods {#s2}
=======

Assessments of possible change in disease incidence and associated risk factors at this present time are unlikely to yield substantial findings given that near-universal health coverage was only recently achieved in China and the lag-times on these outcomes make them more suitable to long-term follow-up. However, the influence of the exogenous expansion in health coverage may be observable within the short-term by tracking 'health service amenable mortality'[@R21] before and subsequent to 2009. The hypothesis is that the near-universal health coverage will have helped to raise standards of living, enhance health promotion and promoted greater equity of access to life-saving health services. The impact would then manifest in downward trends in mortality attributable to preventable causes, such as stroke and ischaemic heart disease (IHD).

To enhance this pre--post time-series analysis we leveraged a negative outcome study design[@R22] wherein causes of death that could not have been affected by the health reforms were also analysed. This analysis of so-called 'negative outcomes' provides additional foundations for falsifiability of the main hypothesis that expansion of health service coverage had a favourable impact on health service amenable mortality. For this purpose, we selected oesophageal and pancreatic cancers specifically due to their short survival times,[@R23] [@R24] as well as the broader group of mortality causes that are not classified as 'amenable'.

Access to annual mortality counts for 161 'disease surveillance points' (DSP) was provided by the Chinese Center for Disease Control and Prevention (China CDC). The DSP is nationally representative and covers a sample population of approximately 73 million people, including urban and rural counties in all 31 provinces, municipalities and autonomous regions within China. Amenable mortality ([table 1](#BMJOPEN2015009370TB1){ref-type="table"}) and other mortality counts were stratified by year, gender and age group (50--59 years, 60--69 years, 70--79 years, 80+ years) at the DSP level for years 2006--2012 inclusive. Population counts from the 2010 census were used to ascertain denominators. Socioeconomic circumstances were measured using the mean years of education among residents within each DSP, also extracted from the 2010 census.

###### 

Amenable mortality definition

  No   Name                                                         Age     ICD10
  ---- ------------------------------------------------------------ ------- ---------------------------
  1    Intestinal infections                                        0--14   A00-A09
  2    Tuberculosis                                                 0--74   A15-A19, B90
  3    Other infectious (diphtheria, tetanus, poliomyelitis)        0--74   A36, A35,A80
  4    Whooping cough                                               0--14   A37
  5    Septicaemia                                                  0--74   A40-A41
  6    Measles                                                      1--14   B05
  7    Malignant neoplasm of colon and rectum                       0--74   C18-C21
  8    Malignant neoplasm of skin                                   0--74   C44
  9    Malignant neoplasm of breast                                 0--74   C50
  10   Malignant neoplasm of cervix uteri                           0--74   C53
  11   Malignant neoplasm of cervix uteri and body of the uterus    0--44   C54, C55
  12   Malignant neoplasm of testis                                 0--74   C62
  13   Hodgkin\'s disease                                           0--74   C81
  14   Leukaemia                                                    0--44   C91-C95
  15   Diseases of the thyroid                                      0--74   E00-E07
  16   Diabetes mellitus                                            0--49   E10-E14
  17   Epilepsy                                                     0--74   G40-G41
  18   Chronic rheumatic heart disease                              0--74   I05-I09
  19   Hypertensive disease                                         0--74   I10-I13, I15
  20   Ischaemic heart disease                                      0--74   I20-I25
  21   Cerebrovascular disease                                      0--74   I60-I69
  22   All respiratory diseases (excluding pneumonia/influenza)     1--14   J00-J09, J20-J99
  23   Influenza                                                    0--74   J10-J11
  24   Pneumonia                                                    0--74   J12-J18
  25   Peptic ulcer                                                 0--74   K25-K27
  26   Appendicitis                                                 0--74   K35-K38
  27   Abdominal hernia                                             0--74   K40-K46
  28   Cholelithiasis and cholecystitis                             0--74   K80-K81
  29   Nephritis and nephrosis                                      0--74   N00-N07, N17-N19, N25-N27
  30   Benign prostatic hyperplasia                                 0--74   N40
  31   Maternal deaths                                              All     O00-O99
  32   Congenital cardiovascular anomalies                          0--74   Q20-Q28
  33   Perinatal deaths, all causes excluding stillbirths           All     P00-P96, A33, A34
  34   Misadventures to patients during surgical and medical care   All     Y60-Y69, Y83-Y84

Descriptive analysis was conducted by calculating the mean annual mortality count for each cause of death for 2006--2012 inclusive. Statistical analysis was conducted via multilevel negative binomial regression with random coefficients to investigate potential spatiotemporal variation in each mortality count.[@R25] An assumption of a standard random intercept multilevel model is that the relationship between and outcome and exposure is the same regardless of the higher level unit, such as a geographic area. By fitting a random coefficient between DSPs and time in our models, we allowed the relationship between mortality and time to vary between DSPs, henceforth making potential geographic deviations in mortality trends (ie, spatiotemporal variation) more observable.

Initial models were fitted with gender, age group and year as fixed effects. The year variable was fitted as in the form of linear and square terms to explore for potential curvilinear trends. This was to help account for the hierarchical data structure, wherein each DSP-level mortality count was stratified by gender, age group and year. Henceforth, level 1 within the model was the DSP-level mortality count for every combination of gender, age group and year, nested within DSPs at level 2. Linear and square functions of year were fitted into the model to assess for deviation in the mortality trends through time. The degree of potential spatiotemporal variation was assessed by observing the covariance of the random slopes. DSP-level variances were re-expressed as median rate ratios (MRR). The DSP-level mean years of education was then added to each model along with an interaction with year to explore whether there was change in the level of socioeconomic inequity over the time period. All fixed effect parameters were exponentiated to rate ratios (RR) and 95% CIs. All analyses were conducted in MLwIN V.2.30 using penalised quasi-likelihood with second order Taylor series expansion to correct for downwardly biased variances.

Results {#s3}
=======

Mean health service amenable mortality was observed at 151.5/100 000 in 2006, rising to 164.1/100 000 by 2008, but then decreasing from 2009 onwards to 150.7/100 000 by 2012 ([table 2](#BMJOPEN2015009370TB2){ref-type="table"}). Stroke mortality appeared to follow a similar inverted parabolic trend, whereas IHD mortality increased across the study period. Non-amenable mortality increased from 453.7/100 000 in 2006 to 495.0/100 000 in 2008, falling to 487.2/100 000 by 2012. Mortality from pancreatic cancer increased across the study period, but deaths from oesophageal cancer decreased.

###### 

Mortality count for each cause of death per 100 000 people, by year

  Year   Amenable   Ischaemic heart disease   Stroke   Non-amenable   Pancreatic cancer   Oesophageal cancer
  ------ ---------- ------------------------- -------- -------------- ------------------- --------------------
  2006   151.5      58.5                      120.0    453.7          3.2                 12.3
  2007   154.6      70.3                      127.7    468.6          3.7                 13.0
  2008   164.1      78.3                      144.8    495.0          3.7                 12.7
  2009   155.3      81.7                      141.9    473.2          3.7                 11.9
  2010   151.6      85.6                      142.6    471.1          3.7                 11.1
  2011   152.6      89.8                      141.7    469.9          4.2                 10.8
  2012   150.7      96.4                      141.6    478.2          4.1                 10.7

Substantial geographical variation was observed for mortality counts from stroke (MRR 1.76), IHD (1.99; [table 3](#BMJOPEN2015009370TB3){ref-type="table"}), oesophageal cancer (2.76) and pancreatic cancer (1.95; [table 4](#BMJOPEN2015009370TB4){ref-type="table"}). The spatial patterning of health service amenable (1.49) and non-amenable (1.28) mortality counts was less varied by comparison ([table 5](#BMJOPEN2015009370TB5){ref-type="table"}). In models unadjusted for socioeconomic circumstances (model 1s, [tables 3](#BMJOPEN2015009370TB3){ref-type="table"}[](#BMJOPEN2015009370TB4){ref-type="table"}--[5](#BMJOPEN2015009370TB5){ref-type="table"}), stroke and IHD mortality increased but then curved downward over time period ([table 3](#BMJOPEN2015009370TB3){ref-type="table"}). Deaths from oesophageal cancer also reduced but those from pancreatic cancer increased ([table 4](#BMJOPEN2015009370TB4){ref-type="table"}). Both health service amenable and non-amenable causes of death appeared to decline across the study period ([table 5](#BMJOPEN2015009370TB5){ref-type="table"}). The covariances indicated a slight narrowing of the geographic variation of these mortality counts through the study period.

###### 

Spatiotemporal trajectories and socioeconomic inequities in mortality from stroke and ischaemic heart disease

                                     Stroke mortality         Ischaemic heart disease mortality                            
  ---------------------------------- ------------------------ ----------------------------------- ------------------------ ------------------------
  *Fixed part*                       Rate Ratio (95% CI)                                                                   
  Year                               1.08 (1.04 to 1.13)      1.09 (1.05 to 1.13)                 1.10 (1.07 to 1.12)      1.10 (1.07 to 1.13)
  Year^2^                            0.99 (0.98 to 0.99)      0.99 (0.98 to 0.99)                 0.99 (0.99 to 0.99)      0.99 (0.99 to 0.99)
  Gender (ref: male)                                                                                                       
   Female                            0.55 (0.54 to 0.57)      0.55 (0.54 to 0.57)                 0.45 (0.43 to 0.46)      0.45 (0.43 to 0.46)
  Age group (ref: 50--59 years)                                                                                            
   60--69                            2.92 (2.84 to 2.99)      2.92 (2.84 to 2.99)                 2.58 (2.51 to 2.65)      2.58 (2.51 to 2.65)
   70--79                            9.77 (9.52 to 10.02)     9.77 (9.52 to 10.02)                8.28 (8.06 to 8.51)      8.28 (8.06 to 8.51)
   80+                               25.53 (24.89 to 26.19)   25.53 (24.89 to 26.19)              28.65 (27.87 to 29.44)   28.65 (27.87 to 29.44)
  Gender×age group (years)                                                                                                 
   Female×60--69                     1.10 (1.06 to 1.15)      1.10 (1.06 to 1.15)                 1.37 (1.32 to 1.43)      1.37 (1.32 to 1.43)
   Female×70--79                     1.25 (1.21 to 1.30)      1.25 (1.21 to 1.30)                 1.77 (1.70 to 1.84)      1.77 (1.70 to 1.84)
   Female×80+                        1.47 (1.41 to 1.52)      1.47 (1.41 to 1.52)                 2.07 (1.98 to 2.15)      2.07 (1.98 to 2.15)
  Mean years of education                                     0.96 (0.90 to 1.02)                                          1.16 (1.08 to 1.25)
  Year×Mean years of education                                0.94 (0.91 to 0.96)                                          0.97 (0.95 to 0.98)
  Year^2^×Mean years of education                             1.01 (1.00 to 1.01)                                          1.00 (1.00 to 1.01)
  *Random part*                                                                                                            
  DSP×Year                                                                                                                 
   Intercept variance (SE) \[MOR\]   0.350 (0.041) \[1.76\]   0.347 (0.041) \[1.75\]              0.521 (0.060) \[1.99\]   0.485 (0.056) \[1.94\]
   Covariance (SE)                   −0.094 (0.015)           −0.101 (0.015)                      −0.043 (0.010)           −0.036 (0.010)
   Slope variance (SE)               0.060 (0.008)            0.051 (0.007)                       0.018 (0.003)            0.016 (0.003)
  DSP×Year^2^                                                                                                              
   Intercept variance (SE) \[MOR\]   0.010 (0.002) \[1.10\]   0.011 (0.002) \[1.11\]              0.004 (0.001) \[1.06\]   0.003 (0.001) \[1.05\]
   Covariance (SE)                   −0.007 (0.001)           −0.006 (0.001)                      −0.002 (\<0.001)         −0.002 (\<0.001)
   Slope variance (SE)               0.001 (\<0.001)          0.001 (\<0.001)                     \<0.001 (\<0.001)        \<0.001 (\<0.001)

DSP, disease surveillance point; MRR, median rate ratio.

###### 

Spatiotemporal trajectories and socioeconomic inequities in mortality from oesophageal and pancreatic cancers

                                     Oesophageal cancer mortality   Pancreatic cancer mortality                            
  ---------------------------------- ------------------------------ ----------------------------- ------------------------ ------------------------
  *Fixed part*                       Rate ratio (95% CI)                                                                   
  Year                               0.98 (0.95 to 1.00)            0.96 (0.93 to 0.99)           1.04 (1.01 to 1.08)      1.06 (1.02 to 1.10)
  Year^2^                            1.00 (0.99 to 1.00)            1.00 (0.99 to 1.00)           1.00 (0.99 to 1.00)      0.99 (0.99 to 1.00)
  Gender (ref: male)                                                                                                       
   Female                            0.20 (0.19 to 0.21)            0.23 (0.21 to 0.24)           0.59 (0.55 to 0.64)      0.59 (0.55 to 0.64)
  Age group (ref: 50--59 years)                                                                                            
   60--69                            2.38 (2.28 to 2.49)            2.44 (2.31 to 2.56)           2.26 (2.12 to 2.42)      2.27 (2.13 to 2.41)
   70--79                            4.67 (4.47 to 4.87)            4.84 (4.60 to 5.09)           4.59 (4.30 to 4.89)      4.56 (4.29 to 4.86)
   80+                               6.85 (6.52 to 7.19)            7.10 (6.72 to 7.50)           6.01 (5.55 to 6.50)      5.91 (5.48 to 6.36)
  Gender×age group (years)                                                                                                 
   Female×60--69                     1.42 (1.31 to 1.54)            1.39 (1.28 to 1.52)           1.14 (1.02 to 1.26)      1.13 (1.02 to 1.25)
   Female×70--79                     1.81 (1.67 to 1.95)            1.72 (1.58 to 1.88)           1.27 (1.15 to 1.41)      1.26 (1.14 to 1.39)
   Female×80+                        2.06 (1.89 to 2.24)            1.88 (1.71 to 2.06)           1.26 (1.12 to 1.42)      1.26 (1.12 to 1.40)
  Mean years of education                                           0.87 (0.77 to 0.98)                                    1.34 (1.25 to 1.44)
  Year×Mean years of education                                      0.97 (0.95 to 0.99)                                    0.98 (0.96 to 1.00)
  Year^2^×Mean years of education                                   1.00 (1.00 to 1.01)                                    1.00 (1.00 to 1.01)
  *Random part*                                                                                                            
  DSP×Year                                                                                                                 
   Intercept variance (SE) \[MOR\]   1.131 (0.133) \[2.76\]         1.189 (0.139) \[2.83\]        0.488 (0.066) \[1.95\]   0.343 (0.049) \[1.75\]
   Covariance (SE)                   −0.024 (0.017)                 −0.022 (0.016)                −0.027 (0.015)           −0.007 (0.012)
   Slope variance (SE)               0.008 (0.003)                  0.003 (0.004)                 0.003 (0.005)            0.002 (0.005)

DSP, disease surveillance point; MRR, median rate ratio.

###### 

Spatiotemporal trajectories and socioeconomic inequities in mortality from health service amenable and non-amenable causes

                                    Health service amenable mortality   Health service non-amenable mortality                            
  --------------------------------- ----------------------------------- --------------------------------------- ------------------------ ------------------------
  *Fixed part*                      Rate Ratio (95% CI)                                                                                  
  Year                              0.98 (0.97 to 1.00)                 0.98 (0.97 to 1.00)                     0.98 (0.96 to 0.99)      0.98 (0.97 to 0.99)
  Year^2^                           1.00 (1.00 to 1.00)                 1.00 (1.00 to 1.00)                     1.00 (1.00 to 1.00)      1.00 (1.00 to 1.00)
  Gender (ref: male)                                                                                                                     
  female                            0.63 (0.62 to 0.64)                 0.63 (0.62 to 0.64)                     0.44 (0.43 to 0.45)      0.44 (0.43 to 0.45)
  Age group (ref: 50--59 years)                                                                                                          
  60--69                            2.74 (2.70 to 2.78)                 2.74 (2.70 to 2.78)                     2.08 (2.05 to 2.12)      2.08 (2.05 to 2.12)
  70--79                            4.21 (4.15 to 4.28)                 4.21 (4.15 to 4.28)                     7.94 (7.82 to 8.07)      7.94 (7.82 to 8.07)
  80+                               0.00 (0.00 to 0.00)                 0.00 (0.00 to 0.00)                     27.19 (26.77 to 27.62)   27.19 (26.77 to 27.62)
  Gender×age group (years)                                                                                                               
  female×60--69                     1.05 (1.02 to 1.07)                 1.05 (1.02 to 1.07)                     1.16 (1.13 to 1.18)      1.16 (1.13 to 1.18)
  female×70--79                     1.10 (1.07 to 1.12)                 1.10 (1.07 to 1.12)                     1.49 (1.46 to 1.53)      1.49 (1.46 to 1.53)
  female×80+                        0.80 (0.38 to 1.68)                 0.80 (0.38 to 1.68)                     1.83 (1.79 to 1.87)      1.83 (1.79 to 1.87)
  Mean years of education                                               0.89 (0.86 to 0.93)                                              0.92 (0.90 to 0.95)
  Year×Mean years of education                                          0.98 (0.97 to 0.99)                                              0.99 (0.98 to 1.00)
  Year^2^×Mean years of education                                       1.00 (1.00 to 1.00)                                              1.00 (1.00 to 1.00)
  *Random part*                                                                                                                          
  DSP×Year                                                                                                                               
  Intercept variance (SE) \[MOR\]   0.176 (0.021) \[1.49\]              0.148 (0.017) \[1.44\]                  0.068 (0.008) \[1.28\]   0.054 (0.007) \[1.25\]
  Covariance (SE)                   −0.003 (0.003)                      −0.007 (0.003)                          −0.008 (0.002)           −0.009 (0.002)
  Slope variance (SE)               0.005 (0.001)                       0.004 (0.001)                           0.004 (0.001)            0.004 (0.001)

DSP, disease surveillance point; MRR, median rate ratio.

Adjusting for socioeconomic circumstances did not markedly change these results. Higher mean years of education in a DSP was associated with lower mortality from stroke, oesophageal, health service amenable and non-amenable mortality, but also higher IHD and pancreatic cancer mortality. Interaction terms indicated some degree of change in the socioeconomic patterning of each mortality outcome over time, with potential narrowing of the gradient for IHD and pancreatic cancer, but widening for other causes of death due to larger reductions in areas with greater years of education.

Discussion {#s4}
==========

Unprecedented change in built, physical and socioeconomic environments associated with rapid urbanisation have manifested unevenly across China, presenting major challenges in disease prevention and detection.[@R26] [@R27] The expansion of health coverage in China as a result of the 2009 reforms has been interpreted an important step towards ensuring access to healthcare and protecting health in the long term. In the short term, has the expansion of health insurance in China had appreciable and early benefits or not? Building on recent work,[@R28] [@R29] our study found mixed evidence for early impacts on mortality. Evidence in support of an early benefit was from the declines in mortality from health service amenable causes. The curvilinear trend of stroke and IHD mortality (rising initially then falling), is not at odds with wider literature on the nutrition transition in China[@R30] but is insufficient to discount an early benefit of the health reform on its own. The concurrent upward trajectory in deaths from pancreatic cancer, which would not be expected to be influenced by the expansion of health coverage, lends support. However, declines in oesophageal cancer mortality and non-amenable causes more generally suggests that reductions in amenable mortality cannot be solely attributed to the 2009 health reform.

The provision of universal health insurance remains a fundamental determinant of health[@R33] and the equivocal findings from our study do not rule out the likely social and economic benefits experienced in many communities across mainland China. A full appreciation of the costs and benefits will only become clearer over time and with epidemiological studies on a range of health outcomes, including time-series analyses of mortality counts. The classification of mortality into causes of death that are recognised to be health service amenable and non-amenable[@R21] has been previously used to assess the impact of a health insurance coverage expansion in Taiwan.[@R18] Our findings are similar in that mortality from amenable and non-amenable causes decreased during the study period. This comparison afforded a negative outcome study design,[@R22] a method which provides stronger grounds for assessing the potential impacts of the health reform intervention. It should be noted, however, that the negative outcome approach does not necessarily provide strong evidence for or against causation. The degree of health coverage policy implementation and benefits likely varied across China but we do not have access to data with which to measure that spatiotemporal diffusion and variation in exposure. It is plausible, for example, that while the less socioeconomically well-off areas and rural communities in particular could have potentially benefitted most from the health reform, these communities may also have been less likely to receive full implementation of the policy within the study period. Were these data to become available to empirically test, it would be possible to compare trends in mortality over time in 'treated' compared with 'untreated' communities within a regression discontinuity framework---an important and under-used study design for evaluations of the causal impact of large-scale policies on health.[@R34] [@R35]

Previous research conducted on China\'s health reforms provide important context for the findings. A large repeated cross-sectional study conducted in 2003, 2008 and 2011 assessed trends in access to healthcare coverage, healthcare activities and financial protection.[@R36] That study reported an increase in healthcare coverage from 29.7% in 2003 to 95.7% by 2011, indicating a dramatic narrowing of inequity of access across regions and between the poorest and wealthiest. However, this was accompanied by a notable increase in hospital admissions.[@R37] In 2011, 12.9% of households had health expenses described as 'catastrophic', with rural residents described as being particularly vulnerable. Another study, focusing on Shaanxi Province in the west of China, reported decreasing medicine prices but also reductions in the availability of the lowest-priced generic medicines in the public and private sectors between 2010 and 2012.[@R38] This underlines our hypothesis that while healthcare insurance has achieved virtually universal coverage in China, there are other related factors such as the availability of medicines and substantial health expenses that are likely to vary geographically and, henceforth, shape spatial inequities in health outcomes. Further research with large sources of routinely collected administrative data, as well as bespoke surveys and qualitative research, are clearly required in order to fully understand the impact of health reforms in China.

Further strengths of our study include the wide geographical scope of the data spanning all 31 provinces and the analyses of disease-specific causes of mortality for comparison purposes. The latter was demonstrably important given the different levels of geographic variation and temporal trajectories in mortality. Although deaths from causes that are and are not amenable to health service intervention are typically grouped separately, an appreciation of heterogeneity within these groups is similarly crucial. It is nonetheless vital to note that DSPs can be very large and within-DSP spatial heterogeneity is unobservable with the data available and, therefore, masks changes in mortality trends at a more local scale and inequities between different population groups, such as urban migrants who do not have permanent residency status within China\'s megacities.[@R39]

It is important to acknowledge that the routine surveillance of mortality counts across a country as vast as China is not trivial. One key challenge is under-reporting of mortality counts. Previous research[@R40] using the DSP mortality data analysed in this study found significantly higher under-reporting of mortality in rural compared with urban areas.[@R41] Explanations for this geographic variation in under-reporting are numerous and could potentially include less experienced medical and administrative staff in rural areas, as well as lower levels of willingness among some bereaved families in rural areas to report deaths.[@R42] [@R43] A study has been published comparing compared capture-mark-recapture techniques using a household survey as gold standard, based on a set of assumptions,[@R44] with propensity score techniques to address under-reporting in China\'s DSP mortality data.[@R40] The authors found the propensity score approach to correct more accurately for under-reporting and it is that adjusted data set that we have analysed in this study. It should be acknowledged, however, that death information for China\'s 'floating' population (eg, urban migrants without permanent residency) is incomplete and could not be analysed as a distinct group within this study.

By focusing on mortality and a relatively short study period of 7 years, including 3 years both prior and subsequent to the 2009 health reforms, other early benefits could not be assessed. These may include better geographical access to healthcare and health promotion activities that enhance community well-being, the results of which are more likely to emerge much later. A limitation of the analysis is that the DSP system, at 161 locations, did not contain information on the healthcare environments provided in each area during the time period. Our use of random coefficient multilevel models circumvented this limitation to a degree by allowing mortality trajectories for every DSP to vary over time (rather than adhere to a fixed slope for the entire country). This is an important methodological strength since, as we have already reflected on, it is unlikely that all areas of China witnessed the same level of change postreform within the short time period of this study. Further work is warranted in this regard to ascertain how much change had occurred in terms of healthcare provision at a local level.

In conclusion, mixed findings in this time-series analysis of health service amenable mortality and negative outcomes indicate that it may be too early to identify appreciable benefits of the expansion of health coverage across China. Far from refuting the position that universal healthcare is an essential social good, our study demonstrates the need for more in-depth epidemiological investigation on the potential benefits for health status, lifestyle and health service use related factors that may yet determine clear reductions in amenable mortality across China.
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